A promising antibody building block may have the affinity you want while carrying potential developability liabilities that limit its use in a multispecific format. Addressing those liabilities without compromising the properties that made the molecule valuable requires optimization across multiple parameters.
Join Alloy scientist Dalton Markrush to explore a rapid, multi-parameter approach that integrates in vitro and in silico workflows to evaluate and optimize developability alongside affinity.
In this webinar, attendees will learn how Alloy:
- Evaluates developability alongside affinity in multispecific building blocks
- Integrates in vitro and in silico workflows for rapid, multi-parameter optimization
- Improves limiting properties while monitoring favorable starting characteristics
- Applies these approaches in practice through representative case studies
Featuring Insights from
Dalton Markrush
,
MS
Dalton Markrush, Associate Director of Protein Analytics at Alloy Therapeutics, develops methods and workflows to accelerate early- and late-stage antibody developability for partner programs. Prior to joining Alloy, Dalton worked on protein analytics and binding at Compass Therapeutics. He holds a master’s degree in biotechnology from Northeastern University.
Sponsored by
.avif)
.avif)
